AI-powered vector design and preclinical validation mark the first step in a multi-phase program aimed at accelerating the path from discovery to clinical assessment in Alzheimer's disease. AUSTIN, TX ...

THE WOODLANDS, Texas, and CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced it ...

Passage Bio, Inc. ((PASG)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Background— It is not known whether further suppression of platelet function can be achieved with clopidogrel beyond that provided by currently recommended loading and maintenance doses. We performed ...

The ORR for the overall population was 51.9%, with a median time to response of 1.6 months. Across subgroups, the ORRs were 75%, 46.9%, and 45.8% in the PARP inhibitor naïve, prior PARP inhibitor ...

Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China Department of Thoracic Surgery, Anhui Chest Hospital, Hefei 230022, Anhui, China ...

SAN CARLOS, Calif. and DALLAS, Oct. 23, 2025 /PRNewswire/ -- CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today ...

SAN CARLOS, Calif. and DALLAS, Oct. 23, 2025 /PRNewswire/ -- CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today ...

Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year, before it entered the second part of a phase 1/2 lymphoma study. The dual-targeting CAR-T, dubbed bbT369, was being ...